Chinese investment in the UK’s leading companies has surged to almost £90bn amid fears that Beijing is buying up Britain.

AstraZeneca inked a US$2.5 billion contract with the city government of Beijing to establish the firm’s sixth global strategic R&D centre, with high-end industrialisation projects conducted in ...

AstraZeneca has announced a $2.5bn investment in the company’s sixth worldwide strategic research and development (R&D) centre in Beijing, China. The initiative, which will take place up to 2029 ...

But the deal is also a much-needed win for China when investment into the world’s second-largest economy is slowing, as trade tensions shift the global focus to the US – AstraZeneca’s biggest market.

In Q4 2024, AstraZeneca PLC (NASDAQ:AZN) was included in 14 billionaire portfolios with a total of $2.20 billion in combined ...

The pharmaceutical firm expects its workforce in Beijing to grow to 1,700 employees and is launching a JV with BioKangtai to help make vaccines; there is also investment into AI. UK and Swedish ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

AstraZeneca announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance ...

AstraZeneca, a British biopharmaceutical company, intends to invest $2.5 billion in a project to establish a global strategic research center in Beijing as part of agreements to develop the ...

This photo taken from Jingshan Hill on Aug. 12, 2024 shows the skyscrapers of the central business district (CBD) on a sunny ...